CRVO — CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 15
- Website: https://www.cervomed.com
Latest SEC filings for CRVO
- 4 — 2026-10-23
- 4 — 2026-10-23
- 4 — 2026-10-23
- 8-K — 2026-09-10
- 8-K — 2026-08-10
- 10-Q — 2026-08-07
- S-8 — 2026-08-07
- 8-K — 2026-08-04
- 8-K — 2026-07-14
- EFFECT — 2026-07-13
Latest CRVO news
- — CervoMed Shows Progress in Treating Rare Aphasia Condition (benzinga.com)
- — CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
- — CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
- — CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit (globenewswire.com)
Educational tool only — not investment advice.